1 PRODUCT NAME
Cetirizine Hydrochloride (BP) 10mg Film Coated Tablets
Cetirizine Hydrochloride (BP) 1 mg/mL Oral Solution

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active ingredient: Cetirizine Hydrochloride 10 mg
Cetirizine Hydrochloride 1 mg/mL
CAS: 83881-51-0

Cetirizine hydrochloride

The molecular weight is 461.8
Cetirizine hydrochloride is an orally active, H1-receptor antagonist.

Chemical name: 2-(2-(4-(4-chlorophenyl) phenylmethyl)-1-piperazinyl) ethoxy) acetic acid hydrochloride.
Cetirizine hydrochloride is a white, crystalline powder and is water-soluble (160 g/100 mL).

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Film-coated tablets: White to off-white capsule-shaped tablet, debossed on one face embossed with “Y” on each side of the break line and blank on the other face.

Oral solution: Clear, colourless liquid with a slight sweet taste and banana flavour.
4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For the relief of:

- Nasal and ocular symptoms of seasonal and perennial allergic rhinitis
- Symptoms of urticaria and insect bites

4.2 Dose and method of administration

The tablets need to be swallowed with a glass of liquid. The solution can be swallowed as such.

For oral use

**Adults**

10mg once daily (1 tablet or 10mL oral solution).

A 5mg starting dose (1 half tablet or 5mL oral solution) may be proposed if this leads to satisfactory control of the symptoms.

If sufficient response is not obtained, the dose may be increased to the maximum recommended dose of 20mg

**Children**

**Children aged from 2 to 6 years:**

2.5mL oral solution twice daily.

**Children aged from 6 to 12 years**

10mg once daily (1 tablet) or 10mL oral solution

A 5mg starting dose (1 half tablet or 5mL oral solution) may be proposed if this leads to satisfactory control of the symptoms.

**Elderly**

Data does not suggest that the dose needs to be reduced in elderly subjects provided that the renal function is normal.

**Renal impairment**

The dosing intervals must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient’s creatinine clearance (CLcr) in mL/min is needed. The CLcr (mL/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:
Dosing adjustments for adult patients with impaired renal function

<table>
<thead>
<tr>
<th>Group</th>
<th>Creatinine clearance (mL/min)</th>
<th>Dosage and frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>≥ 80</td>
<td>10 mg once daily</td>
</tr>
<tr>
<td>Mild</td>
<td>50 – 79</td>
<td>10 mg once daily</td>
</tr>
<tr>
<td>Moderate</td>
<td>30 – 49</td>
<td>5 mg once daily</td>
</tr>
<tr>
<td>Severe</td>
<td>&lt; 30</td>
<td>5 mg once every 2 days</td>
</tr>
<tr>
<td>End-stage renal disease -</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients undergoing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dialysis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and body weight.

**Hepatic impairment**

No dose adjustment is needed in patients with solely hepatic impairment.

4.3 Contraindications

Cetirizine is contraindicated in:

- patients with a history of hypersensitivity to any of the constituents of the formulation, to hydroxyzine or to any piperazine derivatives
- patients with end stage renal impairment at less than 10 mL/min creatinine clearance.

4.4 Special warnings and precautions for use

**Alcohol**

At therapeutic doses, no clinically significant interactions have been demonstrated with
alcohol (for a blood alcohol level of 0.5 g/L). Nevertheless, precaution is recommended if alcohol is taken concomitantly.

**Patients at risk of convulsions**

Caution in epileptic patients and patients at risk of convulsions is recommended.

**Use in Children**

The use of the film-coated tablet and capsule formulation is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation. It is recommended to use the oral solution of cetirizine in children under 6 years.

Due to the amount of some excipients in the formulation, the oral solution is not recommended in children aged less than 2 years.

4.5 Interaction with other medicines and other forms of interaction

**Pharmacokinetic Interactions**

**Lack of interaction**

Pharmacokinetic interaction studies were conducted with cetirizine and pseudoephedrine, antipyrine, cimetidine, ketoconazole, erythromycin, and azithromycin; no pharmacokinetic interactions were observed.

In a multiple dose study of theophylline (400 mg once a day) and cetirizine, there was a small (16%) decrease in clearance of cetirizine, while the disposition of theophylline was not altered by concomitant cetirizine administration.

Studies with cetirizine and cimetidine, glipizide, diazepam, and pseudoephedrine have revealed no evidence of adverse pharmacodynamic interactions.

Studies with cetirizine and azithromycin, erythromycin, ketoconazole, theophylline, antipyrine, and pseudoephedrine have revealed no evidence of adverse clinical interactions.

In particular, concomitant administration of cetirizine with macrolides or ketoconazole has never resulted in clinically relevant ECG changes.

**Ritonavir**

In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the
extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration.

**Food**

The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased by 1 hour.

**Allergy skin test**

Allergy skin tests are inhibited by antihistamines and a wash-out period of 3 days is recommended before performing them.

4.6 Pregnancy and lactation

**Pregnancy (Category B2)**

Category B2: Caution should be exercised in pregnant women.

For cetirizine very rare clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.

**Lactation**

Caution should be exercised in lactating women.

Cetirizine is excreted in human milk at concentrations representing 0.25 to 0.90 those measured in plasma, depending on sampling time after administration.

4.7 Effects on ability to drive and use machines

Objective measurements of driving ability, sleep latency and assembly line performance have not demonstrated any clinically relevant effects at the recommended dose of 10 mg.

Patients intending to drive, engaging in potentially hazardous activities or operating machinery should not exceed the recommended dose and should take their response to the medicinal product into account.

In sensitive patients, concurrent use with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.
4.8 Undesirable effects

Clinical Trial Data

Clinical studies have shown that cetirizine at the recommended dosage has minor adverse effects on the CNS, including somnolence, fatigue, dizziness and headache.

In some cases, paradoxical CNS stimulation has been reported.

Although cetirizine is a selective antagonist of peripheral H1-receptors and is relatively free of anticholinergic activity, isolated cases of micturition difficulty, eye accommodation disorders and dry mouth have been reported.

Instances of abnormal hepatic function with elevated hepatic enzymes accompanied by elevated bilirubin have been reported. Mostly this resolves upon discontinuation of the drug.

Double blind controlled clinical trials comparing cetirizine to placebo or other antihistamines at the recommended dosage (10 mg daily for cetirizine), of which quantified safety data are available, included more than 3200 subjects exposed to cetirizine.

From this pooling, the following adverse reactions were reported for cetirizine 10 mg in the placebo-controlled trials at rates of 1.0% or greater:

<table>
<thead>
<tr>
<th>Adverse reactions:</th>
<th>Cetirizine 10 mg (n=3260)</th>
<th>Placebo (n=3061)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body as a whole – general disorders:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>1.63%</td>
<td>0.95%</td>
</tr>
<tr>
<td>Central and peripheral nervous system disorders:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>1.10%</td>
<td>0.98%</td>
</tr>
<tr>
<td>Headache</td>
<td>7.42%</td>
<td>8.07%</td>
</tr>
<tr>
<td>Gastro-intestinal system disorders:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>0.98%</td>
<td>1.08%</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>2.09%</td>
<td>0.82%</td>
</tr>
<tr>
<td>Nausea</td>
<td>1.07%</td>
<td>1.14%</td>
</tr>
<tr>
<td>Psychiatric disorders:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somnolence</td>
<td>9.63%</td>
<td>5.00%</td>
</tr>
<tr>
<td>Respiratory system disorders:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>1.29%</td>
<td>1.34%</td>
</tr>
</tbody>
</table>
Although statistically more common than under placebo, somnolence was mild to moderate in the majority of cases.

Objective tests as demonstrated by other studies have demonstrated that usual daily activities are unaffected at the recommended daily dose in healthy young volunteers.

Adverse reactions at rates of 1% or greater in children aged from 6 months to 12 years, included in placebo-controlled clinical trials are:

<table>
<thead>
<tr>
<th>Adverse reactions (WHO-ART)</th>
<th>Cetirizine (n=1656)</th>
<th>Placebo (n=1294)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastro-intestinal system disorders</td>
<td>Diarrhoea</td>
<td>1.0%</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Somnolence</td>
<td>1.8%</td>
</tr>
<tr>
<td>Respiratory system disorders</td>
<td>Rhinitis</td>
<td>1.4%</td>
</tr>
<tr>
<td>Body as a whole – general disorders</td>
<td>Fatigue</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

**Post Marketing Experience**
Adverse reactions are ranked under headings of frequency using the following convention:
- Very common ≥1/10
- Common ≥1/100 to <1/10
- Uncommon ≥1/1000 to <1/100
- Rare ≥1/10000 to <1/1000
- Very rare <1/10000
- Not known (cannot be estimated from the available data).

<table>
<thead>
<tr>
<th>Body System</th>
<th>Undesirable effect</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Thrombocytopenia</td>
<td>Very rare</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Hypersensitivity</td>
<td>Rare</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----------------------------------</td>
<td>--------</td>
</tr>
<tr>
<td></td>
<td>Anaphylactic shock</td>
<td>Very rare</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Agitation</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Aggression, confusion, depression, hallucination, insomnia Tic</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Very rare</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Paraesthesia</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Convulsions</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Dysgeusia, dyskinesia, dystonia, syncope, tremor</td>
<td>Very rare</td>
</tr>
<tr>
<td></td>
<td>Amnesia, memory impairment</td>
<td>Not known</td>
</tr>
<tr>
<td>Eye disorder</td>
<td>Accommodation disorder, blurred vision, oculogyration</td>
<td>Very rare</td>
</tr>
<tr>
<td>Cardiac disorder</td>
<td>Tachycardia</td>
<td>Rare</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Diarrhoea</td>
<td>Uncommon</td>
</tr>
<tr>
<td>Hepatobilary disorder</td>
<td>Hepatic function abnormal, transaminases increased, blood bilirubin increased, blood alkaline phosphatase increased, Gamma-glutamyltransferase increased</td>
<td>Rare</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Pruritus, rash</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Urticaria</td>
<td>Rare</td>
</tr>
<tr>
<td></td>
<td>Angioedema, drug eruption</td>
<td>Very rare</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Dysuria, enuresis</td>
<td>Very rare</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Asthenia, malaise</td>
<td>Uncommon</td>
</tr>
<tr>
<td></td>
<td>Oedema</td>
<td>Rare</td>
</tr>
<tr>
<td>Investigations</td>
<td>Weight gain</td>
<td>Rare</td>
</tr>
</tbody>
</table>

**4.9 Overdose**

**Symptoms and signs**

Symptoms observed after an overdose of cetirizine are mainly associated with CNS effects or with effects that could suggest an anticholinergic effect.
Adverse events reported after an intake of at least 5 times the recommended daily dose are: confusion, diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, pruritus, restlessness, sedation, somnolence, stupor, tachycardia, tremor, and urinary retention.

Treatment
There is no known specific antidote to cetirizine.

Should overdose occur, symptomatic or supportive treatment is recommended.

Cetirizine is not effectively removed by dialysis.

5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antihistamines for systematic use, piperazine derivatives.
ATC code: R06AE07

Mechanism of action
Cetirizine, a human metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H1-receptors. In vitro receptor binding studies have shown no measurable affinity for other than H1-receptors.

Ex vivo experiments in mice have shown that systemically administered cetirizine does not significantly occupy the cerebral H1-receptors.

In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: at a dose of 10 mg once or twice daily, it inhibits the late phase recruitment of inflammatory cells, notably eosinophils, in the skin and conjunctiva of atopic subjects submitted to antigen challenge, and the dose of 30 mg/day inhibits the influx of eosinophils in the bronchoalveolar lavage fluid during a late-phase bronchial constriction induced by allergen inhalation in asthmatic subjects. Moreover, cetirizine inhibits the late-phase inflammatory reaction induced in chronic urticaria patients by intradermal administration of kallikrein. It also down-regulates the expression of adhesion molecules, such as ICAM-1 and VCAM-1, which are markers of allergic inflammation.

Onset and duration of action
Studies in healthy volunteers show that cetirizine, at doses of 5 and 10 mg strongly inhibits the wheal and flare reactions induced by very high concentrations of histamine into the skin. The onset of activity after a single 10 mg dose occurs within 20 minutes in 50 % of the subjects and within one hour in 95 %. This activity persists for at least 24 hours after a single administration. In a 35-day study in children aged 5 to 12, no tolerance to the antihistaminic effect (suppression of wheal and flare) of cetirizine was found. When a treatment with
cetirizine is stopped after repeated administration, the skin recovers its normal reactivity to histamine within 3 days.

5.2 Pharmacokinetic properties

Cetirizine exhibits linear kinetics over the range 5 to 60 mg. The terminal half-life is approximately 10 hours and the apparent volume of distribution is 0.50 l/kg.

No accumulation is observed for cetirizine following daily doses of 10 mg for 10 days. The steady-state maximum plasma concentration is approximately 300 ng/mL and is achieved within 1.0 ± 0.5 h.

Plasma protein binding of cetirizine is 93 ± 0.3 %.

Cetirizine does not modify the protein binding of warfarin.

Cetirizine does not undergo extensive first pass metabolism. About two third of the dose are excreted unchanged in urine. The distribution of pharmacokinetic parameters as peak level and area under curve, is unimodal in human volunteer and no differences were observed in the kinetics of cetirizine between white and black adult males. The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased. The extent of bioavailability is similar when cetirizine is given as solutions, capsules or tablets.

Special patient population

Children

The half-life of cetirizine was about 6 hours in children of 6-12 years and 5 hours in children 2-6 years. In infants and toddlers aged 6 to 24 months, it is reduced to 3.1 hours.

Elderly

Following a single 10 mg oral dose, half-life increased by about 50 % and clearance decreased by 40 % in 16 elderly subjects compared to the normal subjects. The decrease in cetirizine clearance in these elderly volunteers appeared to be related to their decreased renal function.

Renal impairment

The pharmacokinetics of the drug was similar in patients with mild impairment (creatinine clearance higher than 40 mL/min) and normal volunteers.
Moderately renally impaired patients had a 3-fold increase in half-life and 70% decrease in clearance compared to normal volunteers.

Patients on haemodialysis (creatinine clearance less than 7 mL/min) given a single oral 10 mg dose of cetirizine had a 3-fold increase in half-life and a 70% decrease in clearance compared to normals. Cetirizine was poorly cleared by haemodialysis. Dosing adjustment is necessary in patients with moderate or severe renal impairment.

**Hepatic impairment**

Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of cetirizine as a single dose had a 50% increase in half-life along with a 40% decrease in clearance compared to healthy subjects.

Dosing adjustment is only necessary in hepatically impaired patients if concomitant renal impairment is present.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

**Tablet core:**
Microcrystalline cellulose
Lactose monohydrate
Colloidal anhydrous silica
Magnesium stearate

**Tablet Coating:**
Hypermellose (E464)
Macrogol 4000
Titanium dioxide (E171)
Polydextrose

**Oral solution**
Glycerol
Propylene glycol
Liquid Sorbitol (non-crystallising) (E420)  
Methyl Parahydroxybenzoate (E218)  
Propyl Parahydroxybenzoate (E216)  
Sodium acetate  
Acetic acid  
Saccharin sodium  
Banana flavour  
Purified water

**Lactose**  
Cetirizine hydrochloride, 10 mg, film-coated tablets contains lactose. Patients with rare hereditary problems of galactose intolerance, (the Lapp lactase deficiency or glucose-galactose malabsorption) should not take this medicine.

**Fructose**  
Patients with rare hereditary problems of fructose intolerance should not take Cetirizine dihydrochloride 1mg/mL oral solution.

**Sorbitol**  
The product contains sorbitol. Patients with rare hereditary problems of galactose intolerance, (the Lapp lactase deficiency or glucose-galactose malabsorption) should not take this medicine.

**Parabens**  
The product contains methylparahydroxybenzoate (methyl paraben) or propylparahydroxybenzoate (propyl paraben), which may cause allergic reactions (possibly delayed).

6.2 Incompatibilities  
Not applicable

6.3 Shelf life  
36 Months

6.4 Special precautions for storage  
Store at or below 30°C.

6.5 Nature and contents of container

**Tablets**  
Transparent or white opaque PVC/PVdC – aluminium blister packs containing 10 or 30 film-coated tablets.
**Oral Solution**
75 mL or 150 mL amber glass bottle with child-resistant polypropylene screw cap incorporating a tamper evident seal.

Measuring device: 5 mL plastic PP measuring spoon graduated at 2.5 mL

**Instructions for Use/Handling:**
Not applicable.

6.6 Special precautions for disposal
No special requirements.

7 MEDICINE SCHEDULE
Pharmacy Only Medicine.

8 SPONSOR
GlaxoSmithKline Consumer Healthcare
Level 11 Zurich House
21 Queen Street
Auckland 1010, New Zealand
FREECALL NZ: 0800 540 144

9 DATE OF FIRST APPROVAL
Cetirizine Hydrochloride (BP) 10mg Film Coated Tablets 25 February 1993
Cetirizine Hydrochloride (BP) 1 mg/mL Oral Solution 17 October 1997

10 DATE OF REVISION OF THE TEXT
09 April 2019

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Transferred to new data sheet template</td>
</tr>
</tbody>
</table>

ZYRTEC is a registered trade mark of the GSK group of companies or its licensor